Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wood, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wood, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 41, 81-93, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy

ORIGINAL ARTICLES

Viral infections in neutropenia--current problems and chemotherapeutic control

MJ Wood
Department of Infection and Tropical Medicine, Heartlands Hospital, Birmingham, UK.

The risk of infection in immunocompromised patients is determined by the nature, degree and duration of the immunosuppressive disease or therapy. Although neutropenia is clearly related to an increased risk of infection, these infections are typically caused by bacteria and fungal pathogens rather than by viruses. Viral infections are predominantly associated with defects in cellular immune function and might not be expected to cause problems in patients whose primary disease is accompanied by neutropenia. The net state of the patient's host-defence mechanisms is, however, a complex interplay between a number of factors, primary among which are the underlying disease and the nature of the therapy being given. In certain periods of neutropenia, therefore, particularly that occurring early after bone marrow transplantation, viral infections are commonly seen. The viruses responsible are chiefly the herpesviruses, both primary infections and reactivation, although other viruses are assuming recognized importance in this setting. This article provides a review of the infections that are encountered during the period of neutropenia in immunocompromised patients and the options available for chemotherapeutic management.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Infect. Immun.Home page
M. H. Braff, M. Zaiou, J. Fierer, V. Nizet, and R. L. Gallo
Keratinocyte Production of Cathelicidin Provides Direct Activity against Bacterial Skin Pathogens
Infect. Immun., October 1, 2005; 73(10): 6771 - 6781.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw
International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences
Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
A. J. Tonks, A. Tonks, R. H. K. Morris, K. P. Jones, and S. K. Jackson
Regulation of platelet-activating factor synthesis in human monocytes by dipalmitoyl phosphatidylcholine
J. Leukoc. Biol., July 1, 2003; 74(1): 95 - 101.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.